AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Chairman's report (verbal update)

6. Appraisal 1: Full Submission
   Levonorgestrel (Jaydess®) for contraception for up to 3 years

7. Appraisal 2: Full Submission
   Peginterferon beta-1a (Plegridy®) in adult patients for the treatment of relapsing remitting multiple sclerosis

8. Appraisal 3: Full Submission
   Avanafil (Spedra®) for the treatment of erectile dysfunction in adult men

9. Appraisal 4: Limited Submission
   Darunavir (Prezista®) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of 3 years and at least 15 kg body weight

    For information

    For information

To protect commercial confidentiality, final appraisal will be conducted in private
12. **Appraisal 5: Full Submission (WPAS)**

Regorafenib (Stivarga®) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib

---

**The meeting will open to the public for the announcement of the recommendation**

Date of next meeting: 15<sup>th</sup> July 2015 in Cardiff